Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial
Garcia-Manero G, Santini V, Zeidan A, Komrokji R, Pozharskaya V, Rose S, Keeperman K, Lai Y, Kalsekar S, Aggarwal B, Miteva D, Valcárcel D, Fenaux P, Shortt J, Della Porta M, Platzbecker U. Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial. Advances In Therapy 2025, 42: 3576-3589. PMID: 40377899, PMCID: PMC12182481, DOI: 10.1007/s12325-025-03208-5.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesEfficacy of erythropoiesis-stimulating agentsRBC-TITransfusion independenceRate of red blood cellsEpoetin alfaTransfusion-DependentMyelodysplastic syndromeClinical benefitRates of treatment-emergent adverse eventsESA-naiveTreatment-emergent adverse eventsLack of clinical benefitResultsAt data cutoffHigh-risk MDSErythropoiesis-stimulating agentsAcute myeloid leukemiaData cutoffIntroductionThe efficacyMethodsEligible patientsConsent withdrawalMyeloid leukemiaSerum erythropoietinRed blood cellsAdverse events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply